HMGB1 and neoplasm: In addition to binding RAGE, tumor-secreted HMGB1 interacts with TIM3, a type I transmembrane protein, and consequently inhibits the transport of nucleic acids to endosomal vesicles, and weakens the anti-tumor effects of DNA vaccines and cytotoxic chemotherapy through the anti-nucleic acid-sensing system67,68.